Brain metastases, cancer that has spread to teh brain from elsewhere in the body, affect an estimated 30% of individuals with advanced cancer, representing a notable challenge in oncology [[1]]. Now, researchers at the University of Hong Kong have identified four distinct subtypes of these brain tumors, suggesting the brain’s unique microenvironment plays a critical role in their growth and response to treatment [[2]]. This detailed analysis of over 1,000 samples could pave the way for more personalized and effective therapies, moving beyond a one-size-fits-all approach to treating this deadly condition [[3]].
Brain metastases, where cancer spreads to the brain, are a leading cause of cancer-related deaths, affecting approximately 30% of patients with advanced solid tumors. Understanding how these tumors develop is crucial for improving treatment outcomes. A new study from the University of Hong Kong’s Li Ka Shing Faculty of Medicine and Faculty of Dentistry suggests that the brain’s unique environment is a primary driver in determining the characteristics of these metastatic tumors, potentially opening doors to more personalized therapies.
The research team analyzed genomic and single-nucleus RNA sequencing data from a cohort of 1,032 brain metastasis samples. This comprehensive analysis revealed four distinct subtypes of brain tumors: a neural-like subtype (BrMS1), an immune-infiltrated subtype (BrMS2), a metabolic subtype (BrMS3), and a proliferative subtype (BrMS4). Each subtype exhibits unique immune characteristics, metabolic processes, biological features, and potential targets for treatment.
The “neural-like subtype” (BrMS1) displays characteristics related to the brain’s microenvironment and shows sensitivity to radiation therapy. The “immune-infiltrated subtype” (BrMS2) is characterized by a high presence of immune cells and is associated with the longest overall survival rates, suggesting immunotherapy could be particularly effective for these patients. The “metabolic subtype” (BrMS3) exhibits unusually high activity in energy metabolism pathways, indicating that treatments targeting these metabolic processes may be beneficial. Finally, the “proliferative subtype” (BrMS4) is defined by rapid cell growth, and targeted therapies may hold promise for treating this type of tumor.
“The immune-suppressive environment of the brain and the blood-brain barrier make treating brain metastases particularly challenging,” said Professor Brian P.Y. Cheung, Clinical Professor of the Department of Surgery, Faculty of Medicine, HKU, and the曾永馨基金教授（臨床神經科學）. “This research demonstrates how different subtypes of tumors interact with the brain’s neural and immune cells, paving the way for the development of innovative combinations of targeted drugs, immunotherapies, and radiation therapy to find effective treatment strategies for these tumors.”
The findings could lead to more effective, individualized treatment plans for patients facing brain metastases. This research highlights the importance of considering the tumor’s environment, not just its origin, when developing cancer therapies.
EastNet website: https://on.cc/EastNet Facebook page: https://www.facebook.com/onccnews/
